Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 1, 2017, Pages 144-153.e8

  Zeiger, Robert S ^a   Schatz, Michael ^a   Dalal, Anand A ^b   Chen, Wansu ^a   Sadikova, Ekaterina ^a   Suruki, Robert Y ^b   Kawatkar, Aniket A ^a   Qian, Lei ^a  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Asthma control; Blood eosinophil count; Controller medication; Cost; Persistent asthma; Severe uncontrolled asthma; Utilization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASTHMA; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHENOTYPE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEVERE UNCONTROLLED ASTHMA; AGED; BLOOD CELL; CELL COUNT; DISEASE COURSE; EOSINOPHIL; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOMARKERS; BLOOD CELLS; CELL COUNT; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84994530397     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.07.015     Document Type: Article

References (50)

1. 1 Wenzel, S.E., Busse, W.W., Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 119 (2007), 14–21.
2. 2 Hekking, P.P., Wener, R.R., Amelink, M., Zwinderman, A.H., Bouvy, M.L., Bel, E.H., The prevalence of severe refractory asthma. J Allergy Clin Immunol 135 (2015), 896–902.
3. 3 Bahadori, K., Doyle-Waters, M.M., Marra, C., Lynd, L., Alasaly, K., Swiston, J., et al. Economic burden of asthma: a systematic review. BMC Pulm Med, 9, 2009, 24.
4. 4 Zeiger, R.S., Schatz, M., Dalal, A.A., Qian, L., Chen, W., Ngor, E.W., et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract 4 (2015), 120–129.
5. 5 Durham, S.R., Kay, A.B., Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy 15 (1985), 411–418.
6. 6 Arbes, S.J. Jr., Calatroni, A., Mitchell, H.E., Gergen, P.J., Age-dependent interaction between atopy and eosinophils in asthma cases: results from NHANES 2005-2006. Clin Exp Allergy 43 (2013), 544–551.
7. 7 Shields, M.D., Brown, V., Stevenson, E.C., Fitch, P.S., Schock, B.C., Turner, G., et al. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clin Exp Allergy 29 (1999), 1382–1389.
8. 8 Durham, S.R., Loegering, D.A., Dunnette, S., Gleich, G.J., Kay, A.B., Blood eosinophils and eosinophil-derived proteins in allergic asthma. J Allergy Clin Immunol 84 (1989), 931–936.
9. 9 Howrylak, J.A., Fuhlbrigge, A.L., Strunk, R.C., Zeiger, R.S., Weiss, S.T., Raby, B.A., Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications. J Allergy Clin Immunol 133 (2014), 1289–1300.
10. 10 Sorkness, C.A., Lemanske, R.F. Jr., Mauger, D.T., Boehmer, S.J., Chinchilli, V.M., Martinez, F.D., et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 119 (2007), 64–72.
11. 11 Tran, T.N., Khatry, D.B., Ke, X., Ward, C.K., Gossage, D., High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 113 (2014), 19–24.
12. 12 Zeiger, R.S., Schatz, M., Li, Q., Chen, W., Gossage, D., Khaty, D., et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract 2 (2014), 741–750.
13. 13 Price, D.B., Rigazio, A., Campbell, J.D., Bleecker, E.R., Corrigan, C.J., Thomas, M., et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3 (2015), 849–858.
14. 14 Szefler, S.J., Phillips, B.R., Martinez, F.D., Chinchilli, V.M., Lemanske, R.F., Strunk, R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005), 233–242.
15. 15 Katz, L.E., Gleich, G.J., Hartley, B.F., Yancey, S.W., Ortega, H.G., Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 11 (2014), 531–536.
16. 16 Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
17. 17 Zeiger, R.S., Hay, J.W., Contreras, R., Chen, W., Quinn, V.P., Seal, B., et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 121 (2008), 885–892.
18. 18 National Committee of Quality Assurance. Available from: http://www.ncqa.org/HEDISQualityMeasurement.aspx. 2015. Assessed April 19, 2015.
19. 19 Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
20. 20 Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
21. 21 Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
22. 22 Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
23. 23 Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
24. 24 Arroyave, W.D., Rabito, F.A., Carlson, J.C., The relationship between a specific IgE level and asthma outcomes: results from the 2005-2006 National Health and Nutrition Examination Survey. J Allergy Clin Immunol Pract 1 (2013), 501–508.
25. 25 Knuffman, J.E., Sorkness, C.A., Lemanske, R.F. Jr., Mauger, D.T., Boehmer, S.J., Martinez, F.D., et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 123 (2009), 411–416.
26. 26 Marsh, D.G., Bias, W.B., Ishizaka, K., Genetic control of basal serum immunoglobulin E level and its effect on specific reaginic sensitivity. Proc Natl Acad Sci U S A 71 (1974), 3588–3592.
27. 27 Burrows, B., Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320 (1989), 271–277.
28. 28 Schatz, M., Zeiger, R.S., Vollmer, W.M., Mosen, D., Mendoza, G., Apter, A.J., et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 130 (2006), 43–50.
29. 29 Zeiger, R.S., Schatz, M., Li, Q., Zhang, F., Purdum, A.S., Chen, W., Step-up care improves impairment in uncontrolled asthma: an administrative data study. Am J Manag Care 16 (2010), 897–906.
30. 30 Agency for Health Research Quality. National quality measures clearinghouse. Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=48617. Accessed April 19, 2015.
31. 31 Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999), 902–907.
32. 32 Reilly, M.C., Zbrozek, A.S., Dukes, E.M., The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1993), 353–365.
33. 33 Chen, H., Blanc, P.D., Hayden, M.L., Bleecker, E.R., Chawla, A., Lee, J.H., Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 11 (2008), 231–239.
34. 34 Schatz, M., Zeiger, R.S., Yang, S.J., Weinstein, A.G., Chen, W., Saris-Baglama, R.N., et al. Development and preliminary validation of the Adult Asthma Adherence Questionnaire. J Allergy Clin Immunol Pract 1 (2013), 280–288.
35. 35 EuroQol - Valuation of EQ-5D. Available from: http://www.euroqol.org/about-eq-5d/valuation-of-eq-5d.html. Accessed January 4, 2016.
36. 36 Red Book. Available from: http://sites.truvenhealth.com/redbook/index.html. Accessed January 4, 2016.
37. 37 Zou, G., A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (2004), 702–706.
38. 38 Chen, W., Shi, J., Qian, L., Azen, S.P., Comparison of robustness to outliers between robust poisson models and log-binomial models when estimating relative risks for common binary outcomes: a simulation study. BMC Med Res Methodol, 14, 2014, 82.
39. 39 Ver Hoef, J.M., Boveng, P.L., Quasi-Poisson vs. negative binomial regression: how should we model overdispersed count data?. Ecology 88 (2007), 2766–2772.
40. 40 Zeiger, R.S., Schatz, M., Li, Q., Chen, W., Khatry, D.B., Gossage, D., et al. The association of blood eosinophil counts to future asthma exacerbations in children with persistent asthma. J Allergy Clin Immunol Pract 3 (2015), 283–287.
41. 41 van Veen, I.H., ten, B.A., Gauw, S.A., Sterk, P.J., Rabe, K.F., Bel, E.H., Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 124 (2009), 615–617 617.e1-2.
42. 42 Fowler, S.J., Tavernier, G., Niven, R., High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 135 (2015), 822–824.
43. 43 Strunk, R.C., Szefler, S.J., Phillips, B.R., Zeiger, R.S., Chinchilli, V.M., Larsen, G., et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 112 (2003), 883–892.
44. 44 Schatz, M., Nakahiro, R., Jones, C.H., Roth, R.M., Joshua, A., Petitti, D., Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care 10 (2004), 25–32.
45. 45 Wark, P.A., McDonald, V.M., Gibson, P.G., Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma. Respirology 20 (2015), 1282–1284.
46. 46 Konno, S., Taniguchi, N., Makita, H., Nakamaru, Y., Shimizu, K., Shijubo, N., et al. Distinct phenotypes of cigarette smokers identified by cluster analysis of patients with severe asthma. Ann Am Thorac Soc 12 (2015), 1771–1780.
47. 47 Shein, S.L., Li, H., Gaston, B., Blood eosinophilia is associated with unfavorable hospitalization outcomes in children with bronchiolitis. Pediatr Pulmonol 51 (2015), 77–83.
48. 48 Khatry, D.B., Gossage, D.L., Geba, G.P., Parker, J.M., Jarjour, N.N., Busse, W.W., et al. Discriminating sputum-eosinophilic asthma: accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. J Allergy Clin Immunol 136 (2015), 812–814.
49. 49 Hastie, A.T., Moore, W.C., Li, H., Rector, B.M., Ortega, V.E., Pascual, R.M., et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132 (2013), 72–80.
50. 50 Spector, S.L., Tan, R.A., Is a single blood eosinophil count a reliable marker for “eosinophilic asthma”?. J Asthma 49 (2015), 807–810.